Skip links

We’re fighting chronic inflammation and cancer with precision.

We Create Targeted Therapies With Curative Potential to Make a Real Difference for Patients.

OncoOne was founded to develop precision medicines for inflammation and cancer to improve patient outcomes and quality of life effectively.

Revolutionizing Immunotherapy for Chronic Inflammation & Cancer:

Recent breakthroughs have addressed previously challenging therapeutic targets, poised to reshape standards of patient care. We are at the forefront of this transformative progress.

Revolutionizing Immunotherapy for Chronic Inflammation & Cancer:

Recent breakthroughs have addressed previously challenging therapeutic targets, poised to reshape standards of patient care. We are at the forefront of this transformative progress.

Oncology

Oncology

Cancer is a leading global cause of death, responsible for nearly one in six fatalities, yet treatment options remain limited. We developed two platform technologies, capitalizing on the discovery of oxMIF and our innovative radiotherapy approach, PreTarg-it®. Our innovative therapies precisely target tumor-associated molecules in a variety of cancers to tackle significant unmet needs in oncology.

Chronic Inflammation

Chronic Inflammation

Chronic inflammation is gaining recognition as an uncontrolled "pandemic", substantially affecting patients’ quality of life, while its therapeutic management remains challenging. Harnessing the groundbreaking discovery of oxMIF, which is exclusively found at inflammation sites, we lead a focused strategy to deliver antibody-based therapies directly to affected organs.

Investing

Are You Interested in Investing in Future Precision Medicines?

OncoOne is seeking investors for a Series A+ / B financing and is looking for strategic partnerships to propel the development of our diverse and rich pipeline of highly differentiated new precision medicines.

OncoOne would like to explore strategic partnerships that would:

  • Accelerate the clinical development of its pipeline in oncology and chronic inflammation.
  • Leverage the existing expertise of its partner for selected disease areas and drug development.

OncoOne welcomes offers for:

  • Global Licensing Transaction
  • Strategic Alliance
  • Build-to-Buy

OncoOne is open to:

  • Investors for a Series A+/B financing in Q2 2024 enabling the company to take its first programs into the clinic.
  • Discuss alternative investment approaches, including separate funding of its two platform technologies, Anti-oxMIF antibodies and PreTarg-it®
  • Offers from Corporate Venture Funds for Early Stage strategic investment.

| Public Grants

Home